Deals
Actavis Still Eyes ‘Couple Billion Dollar’ Deals After Allergan
A technician with a vial of Botox, produced by Allergan Inc., in London.
Photographer: Jason Alden/BloombergThis article is for subscribers only.
Actavis Plc Chief Executive Officer Brent Saunders is still on the lookout for acquisition targets while his company digests the $66 billion buyout of Allergan Inc., the drug industry’s largest deal of 2014.
Actavis will take a pause from doing transformational deals that add new therapeutic areas, Saunders said Wednesday in an interview.